Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Emergent Biosolutions Inc. (NYSE:EBS)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired 96,700 shares of Emergent Biosolutions Inc. during the first quarter, representing an investment of approximately $470,000.
• A number of institutional investors increased their stakes in Emergent Biosolutions, with Covestor Ltd raising its stake by 5,458.5% and now owning 2,946 shares.
• Emergent Biosolutions' stock is currently down 4.3%, with a recent price of $5.63 and a market capitalization of $305.60 million.

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Emergent Biosolutions Inc. (NYSE:EBS - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 96,700 shares of the biopharmaceutical company's stock, valued at approximately $470,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.18% of Emergent Biosolutions at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Invesco Ltd. raised its position in shares of Emergent Biosolutions by 70.9% in the fourth quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company's stock valued at $14,722,000 after buying an additional 638,995 shares during the last quarter. Millennium Management LLC raised its position in shares of Emergent Biosolutions by 83.0% in the fourth quarter. Millennium Management LLC now owns 1,481,906 shares of the biopharmaceutical company's stock valued at $14,167,000 after buying an additional 671,947 shares during the last quarter. Palisade Capital Management LP raised its position in shares of Emergent Biosolutions by 21.6% in the first quarter. Palisade Capital Management LP now owns 1,141,589 shares of the biopharmaceutical company's stock valued at $5,548,000 after buying an additional 202,857 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Emergent Biosolutions by 67.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,104,058 shares of the biopharmaceutical company's stock valued at $10,554,000 after buying an additional 444,790 shares during the last quarter. Finally, Two Sigma Investments LP raised its position in shares of Emergent Biosolutions by 13.9% in the fourth quarter. Two Sigma Investments LP now owns 846,766 shares of the biopharmaceutical company's stock valued at $8,095,000 after buying an additional 103,574 shares during the last quarter. Institutional investors and hedge funds own 78.40% of the company's stock.

Emergent Biosolutions Trading Up 4.6%

Shares of NYSE:EBS traded up $0.38 during trading on Friday, reaching $8.62. The stock had a trading volume of 2,226,303 shares, compared to its average volume of 1,251,579. The business has a fifty day moving average price of $6.68 and a 200-day moving average price of $6.69. The company has a quick ratio of 3.51, a current ratio of 6.32 and a debt-to-equity ratio of 1.20. The stock has a market cap of $467.88 million, a P/E ratio of 3.52 and a beta of 1.97. Emergent Biosolutions Inc. has a fifty-two week low of $4.02 and a fifty-two week high of $13.28.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.42. The business had revenue of $140.90 million during the quarter, compared to analyst estimates of $148.55 million. Emergent Biosolutions had a net margin of 16.38% and a return on equity of 24.89%. As a group, analysts anticipate that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Emergent Biosolutions news, Director Keith Katkin sold 7,844 shares of the business's stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $6.30, for a total transaction of $49,417.20. Following the completion of the sale, the director directly owned 86,431 shares in the company, valued at $544,515.30. The trade was a 8.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.20% of the company's stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.